References

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338:469.

2. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate. 1990;16:39.

3. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004;172:1784.

4. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair. 2002;22:3-25.

5. Naka K, Muraguchi T, Hoshii T, et al. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal. 2008;10:1883-94.

6. Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med. 2007;43:332-47.

7. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem. 2001;11:173-86.

8. Bierhoff E, Vogel J, Benz M, et al. Stromal nodules in benign prostatic hyperplasia. Eur Urol. 1996;29:345-54.

9. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic enlargement in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935-44.

10. Michel MC, Mehlburger L, Schumacher H, et al. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. J Urol. 2001;163(6):1725-9.

11. Verhamme K, Dieleman J, Bleumink G, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic enlargement in primary care—the Triumph project. Eur Urol. 2002;42:323-8.

12. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990;17(3):477-86.

13. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978; 15(4):340-5.

14. Thomson AA, Marker PC. Branching morphogenesis in the prostate gland and seminal vesicles. Differentiation. 2006;74(7):382-92.

15. Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J Steroid Biochem Mol Biol. 2003;85(2-5):349-55.

16. Green JS, Holden ST, Bose P, et al. An investigation into the relationship between prostate size, peak urinary flow rate and male erectile dysfunction. Int J Impot Res. 2001;13(6):322-5.

17. Kaufman JM. The effect of androgen supplementation therapy on the prostate. Aging Male. 2003;6(3): 166-74.

18. Kirby RS, Lowe D, Bultitude MI. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol. 1982;54(6):729-31.

19. Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology. 2008;72(2):247-54.

20. Masumori N, Tsukamoto T, Kumamoto Y, et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol. 1996;155(4):1324-7.

21. Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008;22(2):243-58.

22. Belanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 1994;79(4):1086-90.

23. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am. 1990;17(3):461-75.

24. Collins GN, Lee RJ, Russell EB, et al. Ultrasonically determined patterns of enlargement in benign prostatic hyperplasia. Br J Urol. 1993;71(4):451-6.

25. Fingerhut B, Veenema RJ. Histology and radioautography of induced benign enlargement of the mouse prostate. Invest Urol. 1966;4(2):112-24.

26. Ricke WA, McPherson SJ, Bianco JJ, et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J. 2008;22(5):1512-20.

27. Ricke WA, Ishii K, Ricke EA, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer. 2006;118(9):2123-31.

28. Streng TK, Talo A, Andersson KE, et al. A dose dependent dual effect of oestrogen on voiding in the male mouse? BJU Int. 2005;96(7):1126-30.

29. Delongchamps NB, de la Roza G, Chandan V, et al. Evaluation of prostatitis in autopsied prostates—is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol. 2008;179:1736-40.

30. de la Rosette JJ, Witjes WP, Schafer W, et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study. Neurourol Urodyn. 1998;17(2):99-108.

31. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacterial study. J Urol. 1979;121:755-60.

32. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006;16:25-9.

33. Steiner G, Gessl A, Kramer G, et al. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol. 1994;151:480-4.

34. Theyer G, Kramer G, Assmann I. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107.

35. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968;49(3):347-57.

36. Bennett BD, Culberson DE, Petty CS. Histopathology of prostatitis [abstract]. J Urol. 1990;143:265.

37. Weiss JP, Wein A, Jacobs J, et al. Use of nitrofurantoin macro-crystals after transurethral prostatectomy. J Urol. 1983;130:479.

38. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-69.

39. Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999;84:976-81.

40. Gerstenbluth RE, Seftel AD, MacLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol. 2002;167:2267-70.

41. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(9):S3-14.

42. Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int. 2006;97 Suppl 2:7-11.

43. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-84.

44. Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2007;35:109-15.

45. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(7):2562-8.

46. Popp KA. Assignment of patients into the classification of cardiomyopathies. Circulation. 1992;86(5): 1622-33.

47. Hammersten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8(1):29-36.

48. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140(11):989-1002.

49. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep. 2001 ;2(4) :297-301.

50. Wei YH, Lu CY, Lee HC, et al. Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function. Ann N Y Acad Sci. 1998; 854:155-70.

51. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239-47.

52. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956; 11:298-300.

Harman D. The aging process. Proc Natl Acad Sci USA. 1981;78:7124-8.

Ishii T, Miyazawa M, Hartman PS, et al. Mitochondrial superoxide anion (O(2)(-)) inducible

"mev-1" animal models for aging research. BMB Rep. 2011;44(5):298-305.

Untergasser G, Rumpold H, Hermann M, et al. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Exp Gerontol. 1999;34:

275-87.

Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272:12181-8. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-9.

Juul A, Main K, Blum WF, et al. The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, 2 and 3) decrease with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf). 1994;41:85-91. Mehraein-Ghomi F, Lee E, Church DR, et al. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate. 2008;68:924-34. Shigemura K, Sung SY, Kubo H, et al. Reactive oxygen species mediate androgen receptor-and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate. 2007;67:722-31.

Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108:1541-5.

Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-61.

Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-81. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61:60-72.

Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-75.

Siegfried C, Wrenger M, Senge T, et al. Immunhistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res. 1993;21:305-8. Claus S, Berges R, Senge T, et al. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. J Urol. 1997;158:217-21.

Berges RR, Vucanovic J, Epstein JI, et al. Implication of cell cycle kinetic changes during the progression of human prostate cancer. Clin Cancer Res. 1995;1:473-9. Arck PC, Overall R, Spatz K, et al. Towards a "free radical theory of graying": melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. FASEB J. 2006;20:1567-9.

Cho SG, Choi EJ. Apoptotic signaling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol. 2002;35:24-7.

Matsuzawa A, Ichijo H. Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal. 2005;7:472-81.

Assefa Z, Van Laethem A, Garmyn M, et al. Ultraviolet radiation-induced apoptosis in kera-tinocytes: on the role of cytosolic factors. Biochim Biophys Acta. 2005;1755:90-106. Gupta S, Gollapudi S. Molecular mechanisms of TNF-alpha-induced apoptosis in aging human T cell subsets. Int J Biochem Cell Biol. 2005;37:1034-42.

Goswami A, Dikshit P, Mishra A, et al. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun. 2006;342:184-90.

Zhang R, Al-Lamki R, Bai L, et al. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res. 2004;94:1483-91. Imoto K, Kukidome D, Nishikawa T, et al. Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling. Diabetes. 2006;55:1197-204.

77. Kevin CK, Hannah JZ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol. 2007;292:R18-36.

78. Migliaccio E, Giorgio M, Pelicci PG. Apoptosis and aging: role of p66Shc redox protein. Antioxid Redox Signal. 2006;8:600-8.

79. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 1999;402:309-13.

80. Pellegrini M, Finetti F, Petronilli V, et al. p66SHC Promotes T cell apoptosis by inducing mitochondrial dysfunction and impaired Ca2+ homeostasis. Cell Death Differ. 2007;14(2): 338-47.

81. Thompson IM, Coltman CA, Brawley OW, et al. Chemoprevention of prostate cancer. Semin Urol. 1995;13:122-9.

82. Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol. 2000;199:65-116.

83. Asirvatham AJ, Schmidt M, Gao B, et al. Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinology. 2006;147:257-71.

84. Pathak S, Singh R, Verschoyle RD, et al. Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. Cancer Lett. 2008;261:74-83.

85. Miyake H, Hara I, Kamidono S, et al. Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol. 2004;171:1533-6.

86. Fernández-Checa JC, Kaplowitz N, García-Ruiz C, et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol induced defect. Am J Physiol. 1997;273:G7-17.

87. Armstrong JS, Steinauer KK, Hornung B, et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ. 2002;9:252-63.

88. Tsurusaki T, Aoki D, Kanetake H, et al. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab. 2003;88: 1333-40.

89. Linja MJ, Savinainen KJ, Tammela TL, et al. Expression of ERalpha and ERbeta in prostate cancer. Prostate. 2003;55:180-6.

90. Kwon SM, Kim SI, Chun DC, et al. Development of rat prostatitis model by oral administration of isoflavone and its characteristics. Yonsei Med J. 2001;42:395-404.

91. Harris MT, Feldberg RS, Lau KM, et al. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate. 2000;44:19-25.

92. Ho E, Boileau TW, Bray TM. Dietary influences on endocrine-inflammatory interactions in prostate cancer development. Arch Biochem Biophys. 2004;428:109-17.

93. Smith MR, Morton RA, Barnette KG, Sieber PR, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184(4): 1316-21.

94. Ricke WA, McPherson SJ, Bianco JJ, et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J. 2008;22: 1512-20.

95. Naber K, Weidner W. Chronic prostatitis: an infectious disease? J Antimicrob Chemother. 2000;46:157-61.

96. Palapattu GS, Sutcliffe S, Bastain PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2004;26:1170-81.

97. Sugar LM. Inflammation and prostate cancer. Can J Urol. 2006;13 Suppl 1:46-7.

98. Coffey DS. Similarities of prostate and breast cancer: evolution, diet and estrogens. Urology. 2001;57(Suppl):31-8.

99. Brössner C, Petritsch K, Fink K, et al. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urology. 2004;64(4):707-11.

100. Baltaci S, Orhan D, Cogus C, et al. Inducible nitric oxide synthase expression in BPH, low and high grade PIN and prostate carcinoma. BJU Int. 2001;88:100-3.

101. Gradini R, Realacci M, Petrangeli E, et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol. 1999;189:224-9.

102. Di Silverio F, Bosman C, Salvatori M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:72-9.

103. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue remodeling. Exp Gerontol. 2005;40:121-8.

104. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte- derived cytok-ines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 2002;52:43-8.

105. Handisurya A, Steiner GE, Stix U, et al. Differential expression of interleukin-15, a proinflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate. 2001;49:251-62.

106. Konig JE, Senge T, Allhoff EP, et al. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58:121-9.

107. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61:60-72.

108. Kakehi Y, Segawa T, Wu XX, et al. Down-regulation of macrophage inhibitory cytokine-1/ prostate derived factor in benign prostatic hyperplasia. Prostate. 2004;59:351-6.

109. Vykhovanets EV, Resnick MI, Marengo SR. The healthy rat prostate contains high levels of natural killer-like cells and unique subsets of CD4+ helper inducer T cells: implications for prostatitis. J Urol. 2005;173:1004-10.

110. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51:1202-16.

111. Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int. 2006;97(S2):7-11.

112. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314-7.

113. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. J Urol. 2007;177 Suppl 4:34-5.

114. Stock D, Groome PA, Siemens DR. Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am. 2008;35(1):117-30; vii. Review.

115. Merendino RA, Salvo F, Saija A, et al. Malondialdehyde in benign prostatic hypertrophy: a useful marker? Mediators Inflamm. 2003;12:127-8.

116. Rohrmann S, De Marzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;52:43-58.

117. Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyper-plasia. Prostate. 2005;60:153-9.

118. Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2007;51:524-33.

119. Sciarra A, Mariotti G, Salciccia S, Gomez AA, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008;108:254-60.

120. Narayanan NK, Nargi D, Horton L, et al. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. Prostate. 2009;69:133-41.

121. Mechergui YM, Jemaa AB, Mezigh C, et al. The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels. Inflammation. 2009;32(3):202-10.

122. Sandhu JS. Prostate cancer and chronic prostatitis. Curr Urol Rep. 2008;9:328-32.

123. Caruso C, Balistreri CR, Candore G, et al. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother. 2009;58(12): 1919-33.

124. Wong CP, Bray TM, Ho E. Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Lett. 2009;276:38-46.

125. de Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nature. 2007;7:256-69.

126. Harsch KM, Tasch JE, Heston WDW. Immunotherapies for prostate cancer. In: Chang C, editor. Prostate cancer: basic mechanisms and therapeutic approaches. Singapore: World Scientific Publishing; 2005. p. 33-54.

127. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immunomediated inflammation. J Immunol. 2009;182:4056-64.

128. Kogan-Sakin I, Cohen M, Paland N, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia secreted IL-1. Carcinogenesis. 2009;30(4): 698-705.

129. Penna G, Fibbi B, Amuchastegui S, Corsiero E, et al. The vitamin D receptor agonist elocal-citol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/RhoKinase and NF-kB pathways. Prostate. 2009;69:480-93.

130. Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep. 2008;9:272-8.

131. Begley LA, Kasina S, MacDonald J, et al. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-9.

132. Konig JE, Senge T, Allhoff EP, et al. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58:121-9.

133. Steiner G, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyper-plasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83:1131-46.

134. Novara G, Galfano A, Berto RB, et al. Inflammation, apoptosis, and BPH: what is the evidence? Eur Urol Suppl. 2006;5:401-9.

135. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.

136. Fernandez F, de Beer PM, van der Merwe L, Heyns CF. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis. 2008;29(12):2347-50.

137. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future:COX-2 inhibitors for chemopreven-tion and cancer therapy. Med Chem. 2007;7:599-608.

138. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc. 2002;77:219-25.

139. Pathak SK, Sharma RA, Steward WP, et al. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer. 2005;41:61-70.

140. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61:60-72.

141. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodelling. Exp Gerontol. 2005;40:121-8.

142. Rigas B, Sun Y. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer. 2008;98:1157-60.

143. MacLennan GT, Eisenberg R, Fleshman RL, et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol. 2006;176:1012-6.

144. Khandrika L, Kumar B, Koul S, et al. Oxidative stress in prostate cancer. Cancer Lett. 2009;282:125-36.

145. Goodwin AC, Jadallah S, Toubaji A, et al. Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate. 2008;68:766-72.

146. Aydin A, Arsofa-Sarafinovska Z, Sayal A, et al. Oxidative stress and antioxidant in non-met-astatatic prostate cancer and benign prostatic hyperplasia. Clin Biochem. 2006;39:176-9.

147. Jung K, Seidel B, Rudolph B, et al. Antioxidant enzymes in malignant cell lines and in primary cultured prostatic cells. Free Radic Biol Med. 2007;23(1):127-33.

148. Yilmaz MI, Saglam K, Sonmez A, et al. Antioxidant system activation in prostate cancer. Biol Trace Elem Res. 2000;98:13-9.

149. Fleshner NE, Kucuk O. Antioxidant dietary supplements: rationale and current status as a chemopreventive agents for prostate cancer. Urology. 2001;57(Suppl 4A):90-4.

150. Sikka SC. Role of oxidative stress response elements and antioxidants in prostate cancer patho-biology and chemoprevention—a mechanistic approach. Curr Med Chem. 2003;10:2679-92.

151. Ripple MO, Henry WF, Rago RP, et al. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst. 1997;89:40-8.

152. Vykhovanets EV, Shukla S, MacLennan GT, et al. Il-1b-Induced post-transition effect of NF-Kappa B provides time-dependent wave of signals for initial phase of intrapostatic inflammation. Prostate. 2009;69:633-43.

153. Karan D, Holzbeierlein J, Thrasher JB. Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Res. 2009;69(1):2-5.

154. Taoka R, Tsukuda F, Ishikawa M, et al. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol. 2004;171:2330-5.

155. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology. 1999;53(Suppl 3A):29-40.

156. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171:S36-40.

157. Klein EA, Silverman R. Inflammation, infection and prostate cancer. Curr Opin Urol. 2008;18:315-9.

158. Kesarwani P, Ahirwar DK, Mandhani A, et al. IL-10-1082G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol. 2009;27(3):389-96.

159. Licastro F, Bertaccini A, Porcellini E, et al. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels. Anticancer Res. 2008;28:395-400.

160. Saenz-Lopez P, Carretero R, Cozar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer. 2008;8:382.

161. Mahmud SM, Tanguay S, Begin LR, et al. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev. 2006;15:158-64.

162. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other non-steroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97(13):975-80.

163. Hsu AL, Ching TT, Wang DS, et al. The cyclooxygenase-2 inhibitor celecoxib induces apop-tosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275(15):11397-403.

164. Handisurya A, Steiner GE, Stix U, Ecker RC, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate. 2001;49:251-62.

165. Azadzoi K, Pontari M, Vlachiotis J, et al. Canine bladder blood flow and oxygenation: changes induced by filling, contraction and outlet obstruction. J Urol. 1996;155:1459-65.

166. Levin RM, Levin SS, Zhao Y, et al. Cellular and molecular aspects of bladder hypertrophy. Eur Urol. 1997;32 Suppl 1:15-21.

167. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int. 2004;94:738-44.

168. Takeda M, Araki I, Kamiyama M, et al. Diagnosis and treatment of voiding symptoms. Urology. 2003;62:11-9.

169. Webber R. Benign prostatic hyperplasia. Clin Evid. 2004;11:1119-38.

170. Klein EA, Casey G, Silverman R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implication for prevention. Urology. 2006;68:1145-51.

171. Kooiman GG, Martin FL, Williams JA, et al. The influence of dietary and environmental factors on prostate cancer risk. Prostate Cancer Prostatic Dis. 2000;3:256-8.

172. Pandey M, Gupta S. Green tea and prostate cancer: from bench to clinic. Front Biosci (Elite Ed). 2009;1:13-25.

173. Devrim E, Durak I. Is garlic a promising food for benign prostatic hyperplasia and prostate cancer? Mol Nutr Food Res. 2007;51:1319-23.

174. Chan R, Lok K, Woo J. Prostate cancer and vegetable consumption. Mol Nutr Food Res. 2009;53:201-16.

175. Rohrmann S, Giovannucci E, Willett WC, et al. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr. 2007;85: 523-9.

176. Gann PH, Ma J, Giovannucci E, Willett W, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999;59: 1225-30.

177. Peters U, Takata T. Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res. 2008;52:1261-72.

178. Schwarz S, Obermuuller-Jevic OC, Hellmis E, et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr. 2008;138:49-53.

179. Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochem Biophys. 2004;430:127-34.

180. Bureyko T, Hurdle H, Metcalfe JB, et al. Reduced growth and integrin expression of prostate cells cultured with lycopene, vitamin E and fish oil in vitro. Br J Nutr. 2009; 101:990-7.

181. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the physicians' health study II randomized controlled trial. JAMA. 2009;301(1):52-62.

182. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301(1):39-51.

183. Krishnan AV, Moreno J, Nonn L, Swami S, et al. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res. 2007; 22(S2):V74-80.

184. Carraro JC, Raynaud JP, Koch G, Chisholm GD, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate. 1996;29:231-40.

185. Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res. 2000;28:201-9.

186. Buck AC. Phytotherapy for the prostate. Br J Urol. 1996;78:325-36.

187. Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004;172:1792-9.

188. Ookita K, Shiraga T, Matsumura Y. Use of eviprostat for treatment of prostatic hypertrophy. Hinyokika Kiyo. 1966;12:511-7.

189. Kinoshita H, Kawamura N, Miyakita H, et al. The effects of combination therapy eviprostats and tamsulosin hydrochloride (Harnals) for benign prostatic hypertrophy. Hinyouki Geka. 1998;11:1297-305.

190. Boughton-Smith NK, Deakin AM, Follenfant RL, et al. Role of oxygen radicals and arachi-donic acid metabolites in the reverse passive Arthus reaction and carrageenin paw oedema in the rat. Br J Pharmacol. 1993;110:896-902.

191. I ida M, Saito K. Role of endotoxin-like contaminants in the apparent anti-inflammatory activity of bovine superoxide dismutase. Inflamm Res. 1996;45:268-71.

Diet Tweak System

Diet Tweak System

Trying To Lose Weight Can Be Tough. But... Not Losing Weight and Gaining What You Lost Back, Sucks. If you've ever felt that no matter what you do to lose weight nothing seems to work. If you've ever felt that there has got to be some kind of a system or way to lose weight...but just have not found it yet.

Get My Free Ebook


Post a comment